Molecular Biology Reports

, Volume 39, Issue 9, pp 9265–9274 | Cite as

Individual and combined effects of MDM2 SNP309 and TP53 Arg72Pro on breast cancer risk: an updated meta-analysis

  • Hongtao Cheng
  • Biao Ma
  • Ran Jiang
  • Wei Wang
  • Hui Guo
  • Na Shen
  • Dapeng Li
  • Qunzi Zhao
  • Rui Wang
  • Pengfei Yi
  • Yue Zhao
  • Zeming Liu
  • Tao Huang


The tumor suppressor gene TP53 and its negative regulator murine double minute 2 are involved in multiple cellular pathways. Two potentially functional single nucleotide polymorphisms (SNPs) MDM2 SNP309 and TP53 R72P have been extensively investigated to be associated with breast cancer risk. However, the original studies as well as the subsequent meta-analysis, have yielded contradictory results for the individual effect of the two SNPs on breast cancer risk, plus that conflicting results also existed for the combined effects of MDM2 SNP309 and TP53 R72P on breast cancer risk. This meta-analysis aimed to clarify the individual and combined effects of these two genes on breast cancer risk. We performed a meta-analysis of publications with a total 9,563 cases and 9,468 controls concerning MDM2 SNP309 polymorphism and 19,748 cases and 19,962 controls concerning TP53 R72P. Odds ratios (ORs) with 95 % confidence intervals (CIs) were used to assess the strength of the association. In overall meta-analysis, individuals with the MDM2 SNP309TG genotype were associated with a borderline higher breast cancer risk than those with TT genotype (OR = 1.11, 95 % CI: 1.00–1.24, P heterogeneity = 0.007), whereas the TP53 R72P CC or GC genotype had no effects on breast cancer risk. In the stratified analyses, a significant association between MDM2 SNP309 and breast cancer risk were observed in Asian, but null significant association between TP53 R72P and breast cancer risk were found even in various subgroups. Moreover, no significant combined effects of MDM2 SNP309 and TP53 R72P were observed on breast cancer risk. The borderline association between MDM2 SNP309 and breast cancer risk in overall analysis should be treated with caution, and no significant combined effects for the two SNPs on breast cancer risk suggested functional investigations warranted to explore the molecular mechanism of the TP53-MDM2 circuit genes.


MDM2 TP53 Polymorphisms Breast cancer Meta-analysis 


Conflict of interest

The authors have declared no conflict of interest.

Supplementary material

11033_2012_1800_MOESM1_ESM.doc (116 kb)
Supplementary material 1 (DOC 116 kb)


  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90CrossRefPubMedGoogle Scholar
  2. 2.
    Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153–156CrossRefPubMedGoogle Scholar
  3. 3.
    Boyle P, Levin B (eds) (2008) World Cancer Report 2008. International Agency for Research on Cancer, pp 374–375Google Scholar
  4. 4.
    Easton DF (1999) How many more breast cancer predisposition genes are there? Breast Cancer Res 1:14–17CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Pharoah PD, Dunning AM, Ponder BA, Easton DF (2004) Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer 4:850–860CrossRefPubMedGoogle Scholar
  6. 6.
    Antoniou AC, Easton DF (2006) Models of genetic susceptibility to breast cancer. Oncogene 25:5898–5905CrossRefPubMedGoogle Scholar
  7. 7.
    Levine AJ, Finlay CA, Hinds PW (2004) P53 is a tumor suppressor gene. CELL 116: S67-69, 61 p following S69Google Scholar
  8. 8.
    Dumont P, Leu JI, Della Pietra AC III, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357–365CrossRefPubMedGoogle Scholar
  9. 9.
    Levine AJ, Hu W, Feng Z (2006) The P53 pathway: what questions remain to be explored? Cell Death Differ 13:1027–1036CrossRefPubMedGoogle Scholar
  10. 10.
    Economopoulos KP, Sergentanis TN (2010) Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis. Breast Cancer Res Treat 120:211–216CrossRefPubMedGoogle Scholar
  11. 11.
    Zhang Z, Wang M, Wu D, Tong N, Tian Y (2010) P53 codon 72 polymorphism contributes to breast cancer risk: a meta-analysis based on 39 case–control studies. Breast Cancer Res Treat 120:509–517CrossRefPubMedGoogle Scholar
  12. 12.
    Ma Y, Yang J, Liu Z, Zhang P, Yang Z et al (2011) No significant association between the TP53 codon 72 polymorphism and breast cancer risk: a meta-analysis of 21 studies involving 24,063 subjects. Breast Cancer Res Treat 125:201–205CrossRefPubMedGoogle Scholar
  13. 13.
    Wan Y, Wu W, Yin Z, Guan P, Zhou B (2011) MDM2 SNP309, gene–gene interaction, and tumor susceptibility: an updated meta-analysis. BMC Cancer 11:208CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Schmidt MK, Reincke S, Broeks A, Braaf LM, Hogervorst FB et al (2007) Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. Cancer Res 67:9584–9590CrossRefPubMedGoogle Scholar
  15. 15.
    Cox DG, Deer D, Guo Q, Tworoger SS, Hankinson SE et al (2007) The p53 Arg72Pro and MDM2-309 polymorphisms and risk of breast cancer in the nurses’ health studies. Cancer Causes Control 18:621–625CrossRefPubMedGoogle Scholar
  16. 16.
    Singh V, Rastogi N, Mathur N, Singh K, Singh MP (2008) Association of polymorphism in MDM-2 and p53 genes with breast cancer risk in Indian women. Ann Epidemiol 18:48–57CrossRefPubMedGoogle Scholar
  17. 17.
    Lang A, Palmeback Wegman P, Wingren S (2009) The significance of MDM2 SNP309 and p53 Arg72Pro in young women with breast cancer. Oncol Rep 22:575–579PubMedGoogle Scholar
  18. 18.
    Schmidt MK, Tommiska J, Broeks A, van Leeuwen FE, Van’t Veer LJ et al (2009) Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients. Breast Cancer Res 11:R89CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Leu JD, Wang CY, Tsai HY, Lin IF, Chen RC et al (2011) Involvement of p53 R72P polymorphism in the association of MDM2-SNP309 with breast cancer. Oncol Rep 25:1755–1763PubMedGoogle Scholar
  20. 20.
    Koh WP, Van Den Berg D, Jin A, Wang R, Yuan JM et al (2011) Combined effects of MDM2 SNP309 and TP53 R72P polymorphisms, and soy isoflavones on breast cancer risk among Chinese women in Singapore. Breast Cancer Res Treat 130:1011–1109CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Alshatwi AA, Hasan TN, Shafi G, Alsaif MA, Al-Hazzani AA, et al (2012) A single-nucleotide polymorphism in the TP53 and MDM-2 gene modifies breast cancer risk in an ethnic Arab population. Fundam Clin Pharmacol 26:438–443Google Scholar
  22. 22.
    Garcia-Closas M, Lubin JH (1999) Power and sample size calculations in case–control studies of gene–environment interactions: comments on different approaches. Am J Epidemiol 149:689–692CrossRefPubMedGoogle Scholar
  23. 23.
    Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Sjalander A, Birgander R, Hallmans G, Cajander S, Lenner P et al (1996) p53 Polymorphisms and haplotypes in breast cancer. Carcinogenesis 17:1313–1316CrossRefPubMedGoogle Scholar
  25. 25.
    Weston A, Pan CF, Ksieski HB, Wallenstein S, Berkowitz GS et al (1997) p53 Haplotype determination in breast cancer. Cancer Epidemiol Biomarkers Prev 6:105–112PubMedGoogle Scholar
  26. 26.
    Li T, Lu ZM, Guo M, Wu QJ, Chen KN et al (2002) p53 Codon 72 polymorphism (C/G) and the risk of human papillomavirus-associated carcinomas in China. Cancer 95:2571–2576CrossRefPubMedGoogle Scholar
  27. 27.
    Wang-Gohrke S, Becher H, Kreienberg R, Runnebaum IB, Chang-Claude J (2002) Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years. Pharmacogenetics 12:269–272CrossRefPubMedGoogle Scholar
  28. 28.
    Buyru N, Tigli H, Dalay N (2003) p53 Codon 72 polymorphism in breast cancer. Oncol Rep 10:711–714PubMedGoogle Scholar
  29. 29.
    Huang XE, Hamajima N, Katsuda N, Matsuo K, Hirose K et al (2003) Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer 10:307–311CrossRefPubMedGoogle Scholar
  30. 30.
    Katiyar S, Thelma BK, Murthy NS, Hedau S, Jain N et al (2003) Polymorphism of the p53 codon 72 Arg/Pro and the risk of HPV type 16/18-associated cervical and oral cancer in India. Mol Cell Biochem 252:117–124CrossRefPubMedGoogle Scholar
  31. 31.
    Mabrouk I, Baccouche S, El-Abed R, Mokdad-Gargouri R, Mosbah A et al (2003) No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann N Y Acad Sci 1010:764–770CrossRefPubMedGoogle Scholar
  32. 32.
    Kalemi TG, Lambropoulos AF, Gueorguiev M, Chrisafi S, Papazisis KT et al (2005) The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. Cancer Lett 222:57–65CrossRefPubMedGoogle Scholar
  33. 33.
    Tommiska J, Eerola H, Heinonen M, Salonen L, Kaare M et al (2005) Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 11:5098–5103CrossRefPubMedGoogle Scholar
  34. 34.
    Boersma BJ, Howe TM, Goodman JE, Yfantis HG, Lee DH et al (2006) Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst 98:911–919CrossRefPubMedGoogle Scholar
  35. 35.
    Campbell IG, Eccles DM, Choong DY (2006) No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett 240:195–197CrossRefPubMedGoogle Scholar
  36. 36.
    Copson ER, White HE, Blaydes JP, Robinson DO, Johnson PW et al (2006) Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers. BMC Cancer 6:80CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Ma H, Hu Z, Zhai X, Wang S, Wang X et al (2006) Polymorphisms in the MDM2 promoter and risk of breast cancer: a case–control analysis in a Chinese population. Cancer Lett 240:261–267CrossRefPubMedGoogle Scholar
  38. 38.
    Petenkaya A, Bozkurt B, Akilli-Ozturk O, Kaya HS, Gur-Dedeoglu B et al (2006) Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk. Anticancer Res 26:4975–4977PubMedGoogle Scholar
  39. 39.
    Wilkening S, Bermejo JL, Burwinkel B, Klaes R, Bartram CR et al (2006) The single nucleotide polymorphism IVS1 + 309 in mouse double minute 2 does not affect risk of familial breast cancer. Cancer Res 66:646–648CrossRefPubMedGoogle Scholar
  40. 40.
    Wasielewski M, Nagel JH, Brekelmans C, Klijn JG, van den Ouweland A et al (2007) MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling. Breast Cancer Res Treat 104:153–157CrossRefPubMedGoogle Scholar
  41. 41.
    Baynes C, Healey CS, Pooley KA, Scollen S, Luben RN et al (2007) Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk. Breast Cancer Res 9:R27CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Gochhait S, Bukhari SI, Bairwa N, Vadhera S, Darvishi K et al (2007) Implication of BRCA2-26G>A 5′ untranslated region polymorphism in susceptibility to sporadic breast cancer and its modulation by p53 codon 72 Arg>Pro polymorphism. Breast Cancer Res 9:R71CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Khadang B, Fattahi MJ, Talei A, Dehaghani AS, Ghaderi A (2007) Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women. Cancer Genet Cytogenet 173:38–42CrossRefPubMedGoogle Scholar
  44. 44.
    Sprague BL, Trentham-Dietz A, Garcia-Closas M, Newcomb PA, Titus-Ernstoff L et al (2007) Genetic variation in TP53 and risk of breast cancer in a population-based case control study. Carcinogenesis 28:1680–1686CrossRefPubMedGoogle Scholar
  45. 45.
    Lum SS, Chua HW, Li H, Li WF, Rao N et al (2008) MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population. Carcinogenesis 29:754–761CrossRefPubMedGoogle Scholar
  46. 46.
    Zhang W, Jin MJ, Chen K (2007) Association of p53 polymorphisms and its haplotypes with susceptibility of breast cancer. Zhejiang Da Xue Xue Bao Yi Xue Ban 36:561–566PubMedGoogle Scholar
  47. 47.
    Krekac D, Brozkova K, Knoflickova D, Hrstka R, Muller P et al (2008) MDM2SNP309 does not associate with elevated MDM2 protein expression or breast cancer risk. Oncology 74:84–87CrossRefPubMedGoogle Scholar
  48. 48.
    Paulin FE, O’Neill M, McGregor G, Cassidy A, Ashfield A et al (2008) MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism. BMC Cancer 8:281CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Yarden RI, Friedman E, Metsuyanim S, Olender T, Ben-Asher E et al (2008) MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent. Breast Cancer Res Treat 111:497–504CrossRefPubMedGoogle Scholar
  50. 50.
    Sun YF, Leu JD, Chen SM, Lin IF, Lee YJ (2009) Results based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer. BMC Cancer 9:13CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Akkiprik M, Sonmez O, Gulluoglu BM, Caglar HB, Kaya H et al (2009) Analysis of p53 gene polymorphisms and protein over-expression in patients with breast cancer. Pathol Oncol Res 15:359–368CrossRefPubMedGoogle Scholar
  52. 52.
    Aoki MN, da Silva do Amaral Herrera AC, Amarante MK, do Val Carneiro JL, Fungaro MH, et al (2009) CCR5 and p53 codon 72 gene polymorphisms: implications in breast cancer development. Int J Mol Med 23:429–435Google Scholar
  53. 53.
    Denisov EV, Cherdyntseva NV, Litvyakov NV, Slonimskaya EM, Malinovskaya EA et al (2009) TP53 mutations and Arg72Pro polymorphism in breast cancers. Cancer Genet Cytogenet 192:93–95CrossRefPubMedGoogle Scholar
  54. 54.
    Henriquez-Hernandez LA, Murias-Rosales A, Hernandez Gonzalez A, Cabrera De Leon A, Diaz-Chico BN et al (2009) Gene polymorphisms in TYMS, MTHFR, p53 and MDR1 as risk factors for breast cancer: a case–control study. Oncol Rep 22:1425–1433CrossRefPubMedGoogle Scholar
  55. 55.
    Bisof V, Salihovic MP, Narancic NS, Skaric-Juric T, Jakic-Razumovic J et al (2010) TP53 gene polymorphisms and breast cancer in Croatian women: a pilot study. Eur J Gynaecol Oncol 31:539–544PubMedGoogle Scholar
  56. 56.
    Ebner F, Schremmer-Danninger E, Rehbock J (2010) The role of TP53 and p21 gene polymorphisms in breast cancer biology in a well specified and characterized German cohort. J Cancer Res Clin Oncol 136:1369–1375CrossRefPubMedGoogle Scholar
  57. 57.
    Kara N, Karakus N, Ulusoy AN, Ozaslan C, Gungor B et al (2010) P53 codon 72 and HER2 codon 655 polymorphisms in Turkish breast cancer patients. DNA Cell Biol 29:387–392CrossRefPubMedGoogle Scholar
  58. 58.
    Trifa F, Karray-Chouayekh S, Mabrouk I, Baccouche S, Khabir A et al (2010) Haplotype analysis of p53 polymorphisms: Arg72Pro, Ins16bp and G13964C in Tunisian patients with familial or sporadic breast cancer. Cancer Epidemiol 34:184–188CrossRefPubMedGoogle Scholar
  59. 59.
    Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K (2002) A comprehensive review of genetic association studies. Genet Med 4:45–61CrossRefPubMedGoogle Scholar
  60. 60.
    Zhao E, Cui D, Yuan L, Lu W (2012) MDM2 SNP309 polymorphism and breast cancer risk: a meta-analysis. Mol Biol Rep 39:3471–3477Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Hongtao Cheng
    • 1
    • 2
  • Biao Ma
    • 2
  • Ran Jiang
    • 1
  • Wei Wang
    • 2
  • Hui Guo
    • 1
  • Na Shen
    • 1
  • Dapeng Li
    • 1
  • Qunzi Zhao
    • 1
  • Rui Wang
    • 1
  • Pengfei Yi
    • 1
  • Yue Zhao
    • 1
  • Zeming Liu
    • 1
  • Tao Huang
    • 1
  1. 1.Department of Breast Thyroid SurgeryUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhanChina
  2. 2.Department of Breast SurgeryHubei Cancer HospitalWuhanChina

Personalised recommendations